According to Nihon Kohden America, CoMET helps in real-time decisions for management as well as stabilisation of patients by tracking data continuously for identifying subtle physiological changes
CoMET tool has been built to provide early hints of future risk of catastrophic clinical events. (Credit: National Cancer Institute on Unsplash)
Nihon Kohden America, a provider of precision medical products and services, has launched the artificial intelligence (AI) powered CoMET tool, which has been built to provide early hints of future risks of catastrophic clinical events.
CoMET expands to continuous monitoring of event trajectories. It can predict the potential for future risk of critical clinical events such as sepsis, haemorrhage, respiratory failure, cardiogenic shock, and emergent intubation among others.
Nihon Kohden America president and CEO Eiichi Tanaka said: “We understand the growing challenges in hospitals and are committed to providing innovative solutions to empower clinicians and support exceptional patient care.
“Developing CoMET directly supports proactive decision-making for our healthcare guardians and the sustainability of better outcomes.”
According to Nihon Kohden America, CoMET helps in real-time decisions for management as well as stabilisation of patients by tracking data continuously for detecting subtle physiological changes.
Patients can also be ranked by the tool as per predicted risk of severe illness, while displaying trajectories of deterioration and recovery.
With CoMET’s event trajectories, clinicians get a visual tool for identifying possible deterioration in patients, monitoring efficacy of treatment, evaluating patient acuity, and handling suitable staffing ratios.
By applying unit population-specific models, the tool can determine relative risk for critical events, said the company, which is owned by Japan-founded Nihon Kohden.
The models for the tool are said to have been built through machine learning. They are trained to predict using time series of patient lab values, electronic health record data, vital signs, and continuous waveforms.
Nihon Kohden gained ownership of the CoMET technology following its acquisition of Advanced Medical Predictive Devices, Diagnostics and Displays (AMP3D), a predictive algorithms provider.